Suppression of PARP1 enhances PTEN mRNA therapy in castration-resistant prostate cancer by glycolysis disruption

Molecular Therapy Oncology 2026 Open access

Read full text
Authors: Bo Hu, Pengfei Wu, Lulu Zheng, Haiyin Yang, Yuchuan Fan, Jun Yang, Lu Tang, Sudong Kong, Chao Zhu, Minghui Yang, Jiatao Zhang, Qing Huo Liu
+1 more Yuanyu Huang
DOI: 10.1016/j.omton.2026.201133
Cited by: 1
References: 44

Abstract

. Mechanistically, the restoration of PTEN inhibited glycolysis via the PI3K-Akt signaling pathway in CRPC cells, and the silencing of PARP1 further enhanced this effect. Overall, the mPsiP@miLAND developed in this study effectively inhibited the growth of PTEN-deficient prostate tumors, providing a promising strategy to overcome CRPC by exploiting the synergistic effects of PI3K-Akt and PARP inhibition.

Fields of Study & Subjects

PI3K/AKT/mTOR signaling in cancer Prostate Cancer Treatment and Research PARP inhibition in cancer therapy

Publication details

Journal / source
Molecular Therapy Oncology
Publisher
Elsevier BV
Volume
34
Issue
1
Pages
201133–201133
Publication date
20 January 2026
Language
EN